Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by Johnson & Johnson (JNJ) were $2.431B in the second quarter of 2023. Net trade sales were $1.322B in the U.S. and $1.11B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Genmab initiated with a Buy at HSBC
- Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)